S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
New Breakthrough "Living Software" Has Been… (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
New Breakthrough "Living Software" Has Been… (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
New Breakthrough "Living Software" Has Been… (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
New Breakthrough "Living Software" Has Been… (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
NASDAQ:EOLS

Evolus (EOLS) Stock Forecast, Price & News

$8.67
-0.47 (-5.14%)
(As of 10/2/2023 ET)
Compare
Today's Range
$8.65
$9.11
50-Day Range
$7.49
$10.20
52-Week Range
$6.51
$11.49
Volume
449,749 shs
Average Volume
552,319 shs
Market Capitalization
$493.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.40

Evolus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
146.8% Upside
$21.40 Price Target
Short Interest
Bearish
8.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.48mentions of Evolus in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$1.30 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.76) to ($0.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

481st out of 975 stocks

Pharmaceutical Preparations Industry

215th out of 453 stocks


EOLS stock logo

About Evolus (NASDAQ:EOLS) Stock

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS Price History

EOLS Stock News Headlines

Evolus: Gaining Market Share
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
Evolus to Participate in September Conferences
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
Insider Spends US$1.3m Buying More Shares In Evolus
Evolus Director Trades $1.30M In Company Stock
Barclays Reaffirms Their Hold Rating on Evolus (EOLS)
Evolus (EOLS) Receives a Buy from Mizuho Securities
5 Analysts Have This to Say About Evolus
Why Shares of Evolus Are Jumping Thursday
See More Headlines
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Company Calendar

Last Earnings
8/02/2023
Today
10/02/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
215
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.40
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+146.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-74,410,000.00
Pretax Margin
-39.29%

Debt

Sales & Book Value

Annual Sales
$148.62 million
Book Value
$0.33 per share

Miscellaneous

Free Float
53,896,000
Market Cap
$493.93 million
Optionable
Optionable
Beta
1.60
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. David  MoatazediMr. David Moatazedi (Age 45)
    Pres, CEO & Director
    Comp: $1.27M
  • Ms. Sandra Beaver (Age 45)
    Chief Financial Officer
    Comp: $372.23k
  • Dr. Rui Avelar C.CFP (Age 61)
    Dip.SportMed, M.D., Chief Medical Officer and Head of R&D
    Comp: $682.03k
  • Mr. Jeffrey J. Plumer
    Gen. Counsel
  • Mr. Kurt Knab
    VP of Sales
  • Ms. Tomoko Yamagishi-Dressler
    Chief Marketing Officer
  • Ms. Jessica Novak
    Sr. VP of HR













EOLS Stock - Frequently Asked Questions

Should I buy or sell Evolus stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings
or view top-rated stocks.

What is Evolus' stock price forecast for 2023?

4 equities research analysts have issued 12 month price targets for Evolus' shares. Their EOLS share price forecasts range from $18.00 to $27.00. On average, they anticipate the company's stock price to reach $21.40 in the next year. This suggests a possible upside of 146.8% from the stock's current price.
View analysts price targets for EOLS
or view top-rated stocks among Wall Street analysts.

How have EOLS shares performed in 2023?

Evolus' stock was trading at $7.51 at the beginning of the year. Since then, EOLS shares have increased by 15.4% and is now trading at $8.67.
View the best growth stocks for 2023 here
.

Are investors shorting Evolus?

Evolus saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 3,560,000 shares, an increase of 5.3% from the August 31st total of 3,380,000 shares. Based on an average daily trading volume, of 571,100 shares, the short-interest ratio is currently 6.2 days. Approximately 8.4% of the company's shares are sold short.
View Evolus' Short Interest
.

When is Evolus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our EOLS earnings forecast
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. The company earned $49.35 million during the quarter, compared to analyst estimates of $46.12 million. Evolus had a negative net margin of 39.36% and a negative trailing twelve-month return on equity of 507.42%.

What guidance has Evolus issued on next quarter's earnings?

Evolus updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $185.00 million-$195.00 million, compared to the consensus revenue estimate of $187.83 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?
When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $8.67.

How much money does Evolus make?

Evolus (NASDAQ:EOLS) has a market capitalization of $493.93 million and generates $148.62 million in revenue each year. The company earns $-74,410,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis.

How many employees does Evolus have?

The company employs 215 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com.

This page (NASDAQ:EOLS) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -